Bevacizumab, possessing high efficacy and safety, is a monoclonal anti-VEGF antibody and an encouraging target drug for NSCLC, particularly for those patients with advanced NSCLC (Besse et al., 2015; Assoun et al., 2017). This evidence concerns the gene VEGFA and non-small cell lung carcinoma.